India's one-shot dengue vaccine 'DengiAll' reaches 70% enrolment in Phase III trials across 20 national sites.

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s executive leadership team will host the call, which ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development ...

Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and remains a major public health burden. It is currently defined as FEV1/forced vital capacity (FVC) below ...

Clinical trials are the backbone of medical innovations, shaping the therapies and diagnostics that define modern healthcare. Designing and executing a successful trial involves more than scientific ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...